249 related articles for article (PubMed ID: 34283254)
1. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Kochat V; Raman AT; Landers SM; Tang M; Schulz J; Terranova C; Landry JP; Bhalla AD; Beird HC; Wu CC; Jiang Y; Mao X; Lazcano R; Gite S; Ingram DR; Yi M; Zhang J; Keung EZ; Scally CP; Roland CL; Hunt KK; Feig BW; Futreal PA; Hwu P; Wang WL; Lazar AJ; Slopis JM; Wilson-Robles H; Wiener DJ; McCutcheon IE; Wustefeld-Janssens B; Rai K; Torres KE
Acta Neuropathol; 2021 Sep; 142(3):565-590. PubMed ID: 34283254
[TBL] [Abstract][Full Text] [Related]
2. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
3. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
4. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.
Korfhage J; Lombard DB
Mol Cancer Res; 2019 Jul; 17(7):1417-1428. PubMed ID: 31023785
[TBL] [Abstract][Full Text] [Related]
5. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
6.
Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
[TBL] [Abstract][Full Text] [Related]
7. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.
Otsuka H; Kohashi K; Yoshimoto M; Ishihara S; Toda Y; Yamada Y; Yamamoto H; Nakashima Y; Oda Y
Pathol Res Pract; 2018 Mar; 214(3):417-425. PubMed ID: 29482987
[TBL] [Abstract][Full Text] [Related]
9. Loss of PRC2 function promotes MPNST pathogenesis.
Cancer Discov; 2014 Nov; 4(11):OF14. PubMed ID: 25367955
[TBL] [Abstract][Full Text] [Related]
10. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
11. Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss.
Marchione DM; Lisby A; Viaene AN; Santi M; Nasrallah M; Wang LP; Williams EA; Larque AB; Chebib I; Garcia BA; Wojcik JB
Mod Pathol; 2019 Oct; 32(10):1434-1446. PubMed ID: 31175328
[TBL] [Abstract][Full Text] [Related]
12. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumours.
Lyskjaer I; Lindsay D; Tirabosco R; Steele CD; Lombard P; Strobl AC; Rocha AM; Davies C; Ye H; Bekers E; Ingruber J; Lechner M; Amary F; Pillay N; Flanagan AM
J Pathol; 2020 Oct; 252(2):151-164. PubMed ID: 32666581
[TBL] [Abstract][Full Text] [Related]
13. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
[TBL] [Abstract][Full Text] [Related]
14. A Clinicopathologic Study of Head and Neck Malignant Peripheral Nerve Sheath Tumors.
Owosho AA; Estilo CL; Huryn JM; Chi P; Antonescu CR
Head Neck Pathol; 2018 Jun; 12(2):151-159. PubMed ID: 28762137
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.
Brien GL; Bressan RB; Monger C; Gannon D; Lagan E; Doherty AM; Healy E; Neikes H; Fitzpatrick DJ; Deevy O; Grant V; Marqués-Torrejón MA; Alfazema N; Pollard SM; Bracken AP
Nat Genet; 2021 Aug; 53(8):1221-1232. PubMed ID: 34294917
[TBL] [Abstract][Full Text] [Related]
16. BL1391: an established cell line from a human malignant peripheral nerve sheath tumor with unique genomic features.
Tolomeo D; Agostini A; Macchia G; L'Abbate A; Severgnini M; Cifola I; Frassanito MA; Racanelli V; Solimando AG; Haglund F; Mertens F; Storlazzi CT
Hum Cell; 2021 Jan; 34(1):238-245. PubMed ID: 32856169
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
[TBL] [Abstract][Full Text] [Related]
18. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors.
Thangaiah JJ; Westling BE; Roden AC; Giannini C; Tetzlaff M; Cho WC; Folpe AL
Ann Diagn Pathol; 2022 Aug; 59():151967. PubMed ID: 35567887
[TBL] [Abstract][Full Text] [Related]
19. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
20. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]